Viatris Debt to Equity Ratio 2010-2024 | VTRS
Current and historical debt to equity ratio values for Viatris (VTRS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Viatris debt/equity for the three months ending September 30, 2024 was 0.82.
| Viatris Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-09-30 | $24.96B | $19.79B | 1.26 |
| 2024-06-30 | $25.81B | $19.52B | 1.32 |
| 2024-03-31 | $27.33B | $20.01B | 1.37 |
| 2023-12-31 | $27.22B | $20.47B | 1.33 |
| 2023-09-30 | $27.88B | $20.87B | 1.34 |
| 2023-06-30 | $27.85B | $20.84B | 1.34 |
| 2023-03-31 | $28.36B | $20.93B | 1.36 |
| 2022-12-31 | $28.95B | $21.07B | 1.37 |
| 2022-09-30 | $29.48B | $19.18B | 1.54 |
| 2022-06-30 | $31.32B | $19.81B | 1.58 |
| 2022-03-31 | $33.02B | $20.45B | 1.62 |
| 2021-12-31 | $34.35B | $20.49B | 1.68 |
| 2021-09-30 | $34.93B | $21.14B | 1.65 |
| 2021-06-30 | $36.78B | $21.21B | 1.73 |
| 2021-03-31 | $37.57B | $21.42B | 1.75 |
| 2020-12-31 | $38.60B | $22.95B | 1.68 |
| 2020-09-30 | $18.70B | $12.55B | 1.49 |
| 2020-06-30 | $18.41B | $11.75B | 1.57 |
| 2020-03-31 | $18.88B | $11.26B | 1.68 |
| 2019-12-31 | $19.37B | $11.88B | 1.63 |
| 2019-09-30 | $19.59B | $11.46B | 1.71 |
| 2019-06-30 | $19.91B | $11.90B | 1.67 |
| 2019-03-31 | $20.02B | $11.89B | 1.68 |
| 2018-12-31 | $20.57B | $12.17B | 1.69 |
| 2018-09-30 | $21.39B | $12.07B | 1.77 |
| 2018-06-30 | $21.06B | $12.21B | 1.73 |
| 2018-03-31 | $22.01B | $13.18B | 1.67 |
| 2017-12-31 | $22.50B | $13.31B | 1.69 |
| 2017-09-30 | $22.53B | $13.29B | 1.70 |
| 2017-06-30 | $22.67B | $12.83B | 1.77 |
| 2017-03-31 | $22.62B | $11.66B | 1.94 |
| 2016-12-31 | $23.61B | $11.12B | 2.12 |
| 2016-09-30 | $24.71B | $11.83B | 2.09 |
| 2016-06-30 | $18.51B | $10.33B | 1.79 |
| 2016-03-31 | $12.37B | $10.28B | 1.20 |
| 2015-12-31 | $12.50B | $9.77B | 1.28 |
| 2015-09-30 | $11.50B | $9.82B | 1.17 |
| 2015-06-30 | $13.23B | $9.57B | 1.38 |
| 2015-03-31 | $13.03B | $9.09B | 1.43 |
| 2014-12-31 | $12.55B | $3.28B | 3.83 |
| 2014-09-30 | $11.77B | $3.41B | 3.46 |
| 2014-06-30 | $12.25B | $3.35B | 3.65 |
| 2014-03-31 | $12.16B | $3.19B | 3.81 |
| 2013-12-31 | $12.34B | $2.96B | 4.17 |
| 2013-09-30 | $9.67B | $3.23B | 2.99 |
| 2013-06-30 | $9.27B | $2.95B | 3.15 |
| 2013-03-31 | $9.00B | $2.89B | 3.12 |
| 2012-12-31 | $8.58B | $3.36B | 2.56 |
| 2012-09-30 | $8.08B | $3.62B | 2.23 |
| 2012-06-30 | $8.40B | $3.20B | 2.63 |
| 2012-03-31 | $8.16B | $3.78B | 2.16 |
| 2011-12-31 | $8.09B | $3.51B | 2.31 |
| 2011-09-30 | $7.62B | $3.49B | 2.18 |
| 2011-06-30 | $8.13B | $3.88B | 2.09 |
| 2011-03-31 | $7.96B | $3.92B | 2.03 |
| 2010-12-31 | $7.92B | $3.62B | 2.19 |
| 2010-09-30 | $7.86B | $3.54B | 2.22 |
| 2010-06-30 | $7.62B | $2.98B | 2.56 |
| 2010-03-31 | $7.64B | $3.18B | 2.41 |
| 2009-12-31 | $7.66B | $3.15B | 2.43 |
| 2009-09-30 | $7.69B | $3.07B | 2.50 |
| 2009-06-30 | $7.33B | $2.91B | 2.52 |
| 2009-03-31 | $7.25B | $2.65B | 2.74 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $13.010B | $15.427B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $151.685B | 28.04 |
| Elevance Health (ELV) | United States | $90.559B | 11.84 |
| Cencora (COR) | United States | $47.572B | 17.32 |
| Natera (NTRA) | United States | $23.122B | 0.00 |
| DiDi Global (DIDIY) | China | $22.844B | 0.00 |
| ICON (ICLR) | Ireland | $16.164B | 14.40 |
| Avantor (AVTR) | United States | $14.769B | 22.14 |
| Revvity (RVTY) | United States | $14.502B | 24.32 |
| BioMerieux (BMXMF) | France | $14.256B | 0.00 |
| Solventum (SOLV) | United States | $12.919B | 0.00 |
| CochLear (CHEOY) | Australia | $12.848B | 0.00 |
| Medpace Holdings (MEDP) | United States | $11.220B | 31.61 |
| Doximity (DOCS) | United States | $10.877B | 56.56 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $10.037B | 0.00 |
| HealthEquity (HQY) | United States | $9.712B | 48.73 |
| Sonic Healthcare (SKHHY) | Australia | $8.513B | 0.00 |
| Charles River Laboratories (CRL) | United States | $8.502B | 16.43 |
| Amplifon S.p.A (AMFPF) | Italy | $6.136B | 31.28 |
| Bausch + Lomb (BLCO) | Canada | $5.661B | 26.33 |
| BrightSpring Health Services (BTSG) | United States | $3.913B | 83.22 |
| Sotera Health (SHC) | United States | $3.909B | 20.91 |
| Organon (OGN) | United States | $3.835B | 3.87 |
| Surgery Partners (SGRY) | United States | $3.260B | 37.17 |
| Concentras Parent (CON) | United States | $2.958B | 0.00 |
| Alignment Healthcare (ALHC) | United States | $2.885B | 0.00 |
| PACS (PACS) | United States | $2.161B | 0.00 |
| Ardent Health Partners (ARDT) | United States | $2.121B | 0.00 |
| Teladoc Health (TDOC) | United States | $2.061B | 0.00 |
| Progyny (PGNY) | United States | $1.859B | 37.64 |
| GoodRx Holdings (GDRX) | United States | $1.837B | 48.20 |
| Premier (PINC) | United States | $1.821B | 11.08 |
| GeneDx Holdings (WGS) | United States | $1.708B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.409B | 0.00 |
| Agilon Health (AGL) | United States | $1.351B | 0.00 |
| CareDx (CDNA) | United States | $1.217B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.177B | 11.51 |
| Embecta (EMBC) | United States | $1.031B | 7.06 |
| AMN Healthcare Services Inc (AMN) | United States | $0.993B | 6.72 |
| Establishment Labs Holdings (ESTA) | $0.848B | 0.00 | |
| Auna S.A (AUNA) | Luxembourg | $0.602B | 0.00 |
| SBC Medicals (SBC) | United States | $0.533B | 0.00 |
| DocGo (DCGO) | United States | $0.501B | 18.89 |
| Sonida Senior Living (SNDA) | United States | $0.464B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.435B | 0.00 |
| Enhabit (EHAB) | United States | $0.414B | 35.83 |
| QDM (QDMI) | Hong Kong, SAR China | $0.382B | 10.00 |
| MultiPlan (MPLN) | United States | $0.352B | 0.00 |
| Nutex Health (NUTX) | United States | $0.323B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.317B | 0.00 |
| LifeMD (LFMD) | United States | $0.270B | 0.00 |
| Beauty Health (SKIN) | United States | $0.201B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.185B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.159B | 0.00 |
| Biodesix (BDSX) | United States | $0.151B | 0.00 |
| So-Young (SY) | China | $0.104B | 17.63 |
| Ascend Wellness Holdings (AAWH) | United States | $0.086B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.072B | 0.00 |
| Oncology Institute (TOI) | United States | $0.067B | 0.00 |
| ModivCare (MODV) | United States | $0.062B | 3.35 |
| NeueHealth (NEUE) | United States | $0.061B | 1.61 |
| Singular Genomics Systems (OMIC) | United States | $0.050B | 0.00 |
| OncoCyte (OCX) | United States | $0.035B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.031B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.022B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.019B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.009B | 0.00 |
| KindlyMD (KDLY) | United States | $0.007B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.007B | 0.00 | |
| XWELL (XWEL) | United States | $0.006B | 0.00 |
| Aclarion (ACON) | United States | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |